MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318687 | Name: Scopolamine Hydrobromide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Scopolamine HBr acts as antimuscarinics like atropine, but may have more central nervous system effects. It is a non-selective muscarinic antagonist. Presently, scopolamine HBr is a widely used clinically to treat motion sickness.

Chemical Structure

Scopolamine Hydrobromide
Scopolamine Hydrobromide
CAS#114-49-8 (HBr)

Theoretical Analysis

MedKoo Cat#: 318687

Name: Scopolamine Hydrobromide

CAS#: 114-49-8 (HBr)

Chemical Formula: C17H22BrNO4

Exact Mass: 0.0000

Molecular Weight: 384.26

Elemental Analysis: C, 53.14; H, 5.77; Br, 20.79; N, 3.65; O, 16.65

Price and Availability

Size Price Availability Quantity
1g USD 450.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
114-49-8 (HBr) 55-16-3 (HCl) 51-34-3 (free) 6533-68-2 (HBr trihydrate)
Synonym
Scopolamine Hydrobromide, Scopolamine HBr, (-)-Scopolamine hydrobromide, Scoburen,
IUPAC/Chemical Name
(1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (S)-3-hydroxy-2-phenylpropanoate hydrobromide
InChi Key
WTGQALLALWYDJH-MOUKNHLCSA-N
InChi Code
InChI=1S/C17H21NO4.BrH/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10;/h2-6,11-16,19H,7-9H2,1H3;1H/t11-,12-,13-,14+,15-,16+;/m1./s1
SMILES Code
O=C(O[C@H]1C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@](N2C)([H])C1)[C@@H](C4=CC=CC=C4)CO.[H]Br
Appearance
White to off-white crystalline powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Scopolamine competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects.
In vitro activity:
Scopolamine has potential as a treatment against Pythophthora infestans, a pathogen of potato blight. Scopolamine inhibited the mycelial growth of P. infestans with an IC50 value of 4.25 g L-1. Transcriptome analysis suggested that scopolamine led to a downregulation of most P. infestans genes functioning in cell growth, cell metabolism, and pathogenicity. Reference: J Sci Food Agric. 2023 Oct;103(13):6416-6428. https://pubmed.ncbi.nlm.nih.gov/37209269/
In vivo activity:
In a male Wistar rat model of Alzheimer’s disease, scopolamine administration may exacerbate or worsen certain Alzheimer’s disease-related biomarkers. After scopolamine administration, there was increased Aβ deposition in the hippocampus and an increase in GSK3βP9. There was also a state of oxidative stress in scopolamine-treated groups. Reference: Mol Neurobiol. 2020 Sep;57(9):3979-3988. https://pubmed.ncbi.nlm.nih.gov/32638218/
Solvent mg/mL mM
Solubility
DMSO 19.2 50.00
Water 38.4 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 384.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhu Z, Xiong Z, Zou W, Shi Z, Li S, Zhang X, Liu S, Liu Y, Luo X, Ren J, Zhu Z, Dong P. Anti-oomycete ability of scopolamine against Phytophthora infestans, a terrible pathogen of potato late blight. J Sci Food Agric. 2023 Oct;103(13):6416-6428. doi: 10.1002/jsfa.12717. Epub 2023 May 31. PMID: 37209269. 2. Wang X, Zhu X, Ji X, Yang J, Zhou J. Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis. Neuropsychiatr Dis Treat. 2023 May 1;19:1043-1053. doi: 10.2147/NDT.S408794. PMID: 37153351; PMCID: PMC10162387. 3. Hernández-Rodríguez M, Arciniega-Martínez IM, García-Marín ID, Correa-Basurto J, Rosales-Hernández MC. Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats. Mol Neurobiol. 2020 Sep;57(9):3979-3988. doi: 10.1007/s12035-020-02009-x. Epub 2020 Jul 7. PMID: 32638218.
In vitro protocol:
1. Zhu Z, Xiong Z, Zou W, Shi Z, Li S, Zhang X, Liu S, Liu Y, Luo X, Ren J, Zhu Z, Dong P. Anti-oomycete ability of scopolamine against Phytophthora infestans, a terrible pathogen of potato late blight. J Sci Food Agric. 2023 Oct;103(13):6416-6428. doi: 10.1002/jsfa.12717. Epub 2023 May 31. PMID: 37209269.
In vivo protocol:
1. Wang X, Zhu X, Ji X, Yang J, Zhou J. Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis. Neuropsychiatr Dis Treat. 2023 May 1;19:1043-1053. doi: 10.2147/NDT.S408794. PMID: 37153351; PMCID: PMC10162387. 2. Hernández-Rodríguez M, Arciniega-Martínez IM, García-Marín ID, Correa-Basurto J, Rosales-Hernández MC. Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats. Mol Neurobiol. 2020 Sep;57(9):3979-3988. doi: 10.1007/s12035-020-02009-x. Epub 2020 Jul 7. PMID: 32638218.
1: Zhang YL, Li YP. [Simultaneous determination of scopolamine hydrobromide, atropine sulfate, ephedrine hydrochloride and pseudoephedrine hydrochloride in Zhichuanling oral liquid with HPLC]. Zhongguo Zhong Yao Za Zhi. 2013 Oct;38(19):3291-4. Chinese. PubMed PMID: 24422394. 2: Xia T, Liu DD, Shi LF, Hu JH. [Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. Yao Xue Xue Bao. 2011 Aug;46(8):951-4. Chinese. PubMed PMID: 22007521. 3: Li FQ, Yan C, Bi J, Lv WL, Ji RR, Chen X, Su JC, Hu JH. A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromideinto orally disintegrating tablets. Int J Nanomedicine. 2011;6:897-904. doi: 10.2147/IJN.S17900. Epub 2011 Apr 28. PubMed PMID: 21720502; PubMed Central PMCID: PMC3124395. 4: Martin-Flores M, Mercure-McKenzie TM, Campoy L, Erb HN, Ludders JW, Gleed RD. Controlled retrospective study of the effects of eyedrops containing phenylephrine hydrochloride and scopolamine hydrobromide on mean arterial blood pressure in anesthetized dogs. Am J Vet Res. 2010 Dec;71(12):1407-12. doi: 10.2460/ajvr.71.12.1407. PubMed PMID: 21117990. 5: Lü WL, Hu JH, Zhu QG, Li FQ. [Preparation of scopolamine hydrobromide nanoparticles-in-microsphere system]. Yao Xue Xue Bao. 2010 Jul;45(7):914-9. Chinese. PubMed PMID: 20931792. 6: Gupta VD Phd. Chemical stability of scopolamine hydrobromide nasal solution. Int J Pharm Compd. 2009 Sep-Oct;11(5):438-9. PubMed PMID: 23966527. 7: Likar R, Rupacher E, Kager H, Molnar M, Pipam W, Sittl R. [Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study]. Wien Klin Wochenschr. 2008;120(21-22):679-83. doi: 10.1007/s00508-008-1094-2. German. PubMed PMID: 19116709. 8: Cao SL, Zhang QZ, Jiang XG. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy. Acta Pharmacol Sin. 2007 Apr;28(4):584-90. PubMed PMID: 17376300. 9: Doty RL, Bagla R, Misra R, Mueller E, Kerr KL. No influence of scopolamine hydrobromide on odor detection performance of rats. Chem Senses. 2003 Nov;28(9):761-5. PubMed PMID: 14654443. 10: Ceyhan T, Kartal M, Altun ML, Tülemis F, Cevheroglu S. LC determination of atropine sulfate and scopolamine hydrobromide in pharmaceuticals. J Pharm Biomed Anal. 2001 Jun;25(3-4):399-406. PubMed PMID: 11377019. 11: Ahmed S, Sileno AP, deMeireles JC, Dua R, Pimplaskar HK, Xia WJ, Marinaro J, Langenback E, Matos FJ, Putcha L, Romeo VD, Behl CR. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000 Aug;17(8):974-7. PubMed PMID: 11028944. 12: Glaser R, Shiftan D, Drouin M. Conformational Pseudopolymorphism and Solid-State CPMAS NMR Studies for Determination of Solvent-Dependent Solution-State Conformational Preferences for (-)-Scopolamine Hydrobromide/Hydrochloride Salts. J Org Chem. 2000 Mar 24;65(6):1898. PubMed PMID: 10814166. 13: National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Scopolamine Hydrobromide Trihydrate (CAS No. 6533-68-2) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1997 Mar;445:1-277. PubMed PMID: 12594530. 14: Michel A, Drouin M, Glaser R. Solid-state stereochemistry of (-)-scopolamine hydrobromide sesquihydrate, a new polymorph of the anticholinergic drug. J Pharm Sci. 1994 Apr;83(4):508-13. PubMed PMID: 8046605. 15: Statement regarding: Effects of scopolamine hydrobromide on the development of the chick and rabbit embryo. Aust J Biol Sci. 1988;41(4):589-90. PubMed PMID: 3271386. 16: Ogawa N, Haba K, Sora YH, Higashida A, Sato H, Ogawa S. Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochloride on scopolamine hydrobromide-induced impairment in radial maze performance. Clin Ther. 1988;10(6):704-11. PubMed PMID: 3219685. 17: Markkanen YJ, Laurén L, Peltomäki T. Serum antimuscarinic activity after a single dose of oral scopolamine hydrobromide solution measured by radioreceptor assay. Oral Surg Oral Med Oral Pathol. 1987 May;63(5):534-8. PubMed PMID: 3295650. 18: Markkanen YJ, Pihlajamäki K. Oral scopolamine hydrobromide solution as an antisialagogic agent in dentistry. Oral Surg Oral Med Oral Pathol. 1987 Apr;63(4):417-20. PubMed PMID: 3472139. 19: Yamada S, Noda N, Hayakawa J, Uno K. [Determination of scopolamine hydrobromide in seasick remedies by high performance liquid chromatography]. Yakugaku Zasshi. 1984 Feb;104(2):199-203. Japanese. PubMed PMID: 6737230. 20: Jira T, Pohloudek-Fabini R. [Analysis and stability of atropine sulfate and scopolamine hydrobromide. 3: Studies on the stability of tropane alkaloids; 80: contribution to problems in the use of plastic containers for liquid pharmaceuticals]. Pharmazie. 1983 Aug;38(8):520-3. German. PubMed PMID: 6634922.